MedTrace Logo

Opiates and Benzodiazepines on Driving

NCT03447353 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-09-27

Study results available
· View outcomes & findings →

Summary

The aim of this research is to assess drug effects (Xanax and Norco) on driving performance. Researchers will use the Alertness Memory Profiler (AMP) application to compare results to previous related studies.

This study continues a line of research designed to characterize the effects of common recreationally used prescription and illicit drugs with well known stimulant and sedating effects and their relationship to results from the Alertness Memory Profiler (AMP) that included a set of vigilance and memory tasks.

Conditions

  • Driving Behavior

Interventions

DRUG

Xanax 1Mg Tablet

Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco

DRUG

Norco 10Mg-325Mg Tablet

Single dose on two of the four study visits, one in conjunction with 1mg alprazolam

DRUG

Placebo Oral Tablet

Single dose on two of the four study visits, double dose on one of the four study visits

Sponsors & Collaborators

  • Timothy L. Brown

    lead OTHER

Principal Investigators

  • Timothy L Brown, Ph.D. · National Advanced Driving Simulator at the University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-14
Primary Completion
2016-10-25
Completion
2016-10-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03447353 on ClinicalTrials.gov